Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 8/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31544059 | 0.91 | SLC28A1 (0.47) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31598954 | 0.88 | P2RY2 (0.60) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31750991 | 0.86 | P2RY2 (0.49) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15329048 | 0.85 | POLA1 (0.52) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31657660 | 0.84 | P2RY2 (0.52) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL93614 | 0.84 | SLC28A1 (0.54) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29414441 | 0.82 | SLC28A1 (0.46) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL38661234 | 0.80 | P2RY2 (0.64) | P2RY2P2RY4P2RY14P2RY6POLA1 | |
| SCHEMBL31552872 | 0.80 | PDE3A (0.54) | P2RY2SLC29A1POLA1 | |
| SCHEMBL564840 | 0.79 | P2RY2 (0.45) | P2RY2P2RY4SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | HANGZHOU TIANLONG PHARMACEUTICAL CO., LTD. (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4678747-A2 | DOUBLE-STRANDED RNAI AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025077949-A1 | MODIFICATION TEMPLATE FOR IMPROVING INHIBITORY EFFECT OF DOUBLE-STRANDED OLIGONUCLEOTIDE ON TARGET GENE, COMBINATION THEREOF AND USE THEREOF | 杭州天龙药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| WO-2025061911-A1 | METHODS OF PRODUCING NUCLEOTIDE TRIPHOSPHATES (NTPS) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | NSUN2, EIF2AK2, METTL16 | P2RY2 4189/4885P2RY4 4275/4885SLC28A1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.